Recurrent Miscarriage – does progesterone improve outcomes?
The researchers sought to determine if 400 mg progesterone vaginal capsules, given twice a day could increase live births beyond 24 weeks when compared to placebo, when administered to women with history of recurrent miscarriage (3 or more first trimester losses). Results showed that:
The live birth rate in the progesterone group was 65.8% compared to 63.3% in the placebo group, which was not a statistically significant difference (p=0.45)
There were no differences in secondary outcomes which included clinical pregnancy between 6 to 8 weeks, ongoing pregnancy at 12 weeks, ectopic rate and stillbirths, neonatal survival rates or congenital anomalies
Progesterone is required for a healthy pregnancy and progesterone has been used to treat women with recurrent pregnancy loss. This multi-centered randomized controlled trial sought to determine if providing vaginal progesterone in the first trimester would improve live birth rates by at least 10%. The vaginal capsules were administered from the date of randomization (no later than 6 weeks gestation) until 12 completed weeks of gestation.
Progesterone administered in the first trimester, using the dosage and route in this study, did not improve live births nor secondary outcomes in women who had a history of unexplained first trimester losses
This study does not address administration of progesterone prior to conception
Please sign up or log in to your ObGFirst to access this Premium Content
Media - Internet
Computer System Requirements
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan